CN106604928A - 用于α‑螺旋拟态的大环肽模拟物 - Google Patents

用于α‑螺旋拟态的大环肽模拟物 Download PDF

Info

Publication number
CN106604928A
CN106604928A CN201580029301.XA CN201580029301A CN106604928A CN 106604928 A CN106604928 A CN 106604928A CN 201580029301 A CN201580029301 A CN 201580029301A CN 106604928 A CN106604928 A CN 106604928A
Authority
CN
China
Prior art keywords
group
amino acid
macrocyclic
peptidomimetic molecule
macrocyclic peptidomimetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580029301.XA
Other languages
English (en)
Chinese (zh)
Inventor
鲁迪·法桑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of CN106604928A publication Critical patent/CN106604928A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201580029301.XA 2014-04-02 2015-04-01 用于α‑螺旋拟态的大环肽模拟物 Pending CN106604928A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461973994P 2014-04-02 2014-04-02
US61/973,994 2014-04-02
PCT/US2015/023883 WO2015153761A2 (en) 2014-04-02 2015-04-01 Macrocyclic peptidomimetics for alpha-helix mimicry

Publications (1)

Publication Number Publication Date
CN106604928A true CN106604928A (zh) 2017-04-26

Family

ID=54241434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580029301.XA Pending CN106604928A (zh) 2014-04-02 2015-04-01 用于α‑螺旋拟态的大环肽模拟物

Country Status (6)

Country Link
US (1) US10294273B2 (https=)
EP (1) EP3126375B1 (https=)
JP (1) JP6642887B2 (https=)
CN (1) CN106604928A (https=)
CA (1) CA2944651A1 (https=)
WO (1) WO2015153761A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10827064B2 (en) 2016-06-13 2020-11-03 Google Llc Automated call requests with status updates
EP3748558A1 (en) * 2016-06-13 2020-12-09 Google LLC Automated telephone call initiating system and method
US11479581B2 (en) 2017-06-09 2022-10-25 Bristol-Myers Squibb Company Non-chromatographic purification of macrocyclic peptides by a resin catch and release
WO2018232062A1 (en) 2017-06-15 2018-12-20 University Of Washington Macrocyclic polypeptides
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
CN117567639A (zh) * 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
WO2020227313A1 (en) 2019-05-06 2020-11-12 Google Llc Automated calling system
US11158321B2 (en) 2019-09-24 2021-10-26 Google Llc Automated calling system
EP3909230B1 (en) 2020-03-20 2024-10-23 Google LLC Semi-delegated calling by an automated assistant on behalf of human participant
US11303749B1 (en) 2020-10-06 2022-04-12 Google Llc Automatic navigation of an interactive voice response (IVR) tree on behalf of human user(s)
CN118829648A (zh) * 2021-12-10 2024-10-22 默沙东有限责任公司 P53拟肽大环化合物
TW202417465A (zh) 2022-08-23 2024-05-01 日商富士軟片股份有限公司 環肽或其鹽及mdmx抑制劑
WO2024054892A1 (en) * 2022-09-09 2024-03-14 Shape Therapeutics Inc. Therapeutic peptides
US12225158B2 (en) 2022-12-15 2025-02-11 Google Llc System(s) and method(s) for implementing a personalized chatbot
JP2026504093A (ja) 2023-01-16 2026-02-03 アンブレツクス・インコーポレイテツド 抗cd70抗体薬物コンジュゲート
US12581015B2 (en) 2023-03-21 2026-03-17 Google Llc Automating telephone call(s) on behalf of user(s)
WO2024241086A1 (en) 2023-05-24 2024-11-28 Ambrx, Inc. Pegylated bovine interferon lambda and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090388A1 (en) * 2004-03-19 2005-09-29 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US20140057857A1 (en) * 2010-12-15 2014-02-27 The Research Foundation For The State University Of New York Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
BRPI0720306A2 (pt) * 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
DE112009000300T5 (de) * 2008-02-08 2011-01-20 Aileron Therapeutics, Inc., Cambridge Therapeutische Peptidomimetische Makrocyclen
WO2009149339A2 (en) * 2008-06-05 2009-12-10 University Of Maryland, Baltimore P53 activator peptides
CN102203126A (zh) * 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
US9175047B2 (en) * 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102712675A (zh) * 2009-09-22 2012-10-03 爱勒让治疗公司 拟肽大环化合物
ES2711526T3 (es) * 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
WO2012100176A2 (en) * 2011-01-20 2012-07-26 University Of Rochester Macrocyclic compounds with a hybrid peptidic/non-peptidic backbone and methods for their preparation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090388A1 (en) * 2004-03-19 2005-09-29 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US20140057857A1 (en) * 2010-12-15 2014-02-27 The Research Foundation For The State University Of New York Cross-Linked Peptides and Proteins, Methods of Making Same, and Uses Thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JESSICA M. SMITH等: "Modular Assembly of Macrocyclic Organo–Peptide Hybrids Using Synthetic and Genetically Encoded Precursors", 《ANGEWANDTE CHEMIE》 *
JOHN R.等: "Macrocyclization of Organo-Peptide Hybrids through a Dual Bio-orthogonal Ligation: Insights from Structure-Reactivity Studies", 《CHEMBIOCHEM》 *
MARAGANI SATYANARAYANA等: "Diverse organo-peptide macrocycles via a fast and catalyst-free oxime/intein-mediated dual ligation", 《CHEMCOMM》 *

Also Published As

Publication number Publication date
US10294273B2 (en) 2019-05-21
JP2017513826A (ja) 2017-06-01
WO2015153761A2 (en) 2015-10-08
JP6642887B2 (ja) 2020-02-12
EP3126375A2 (en) 2017-02-08
WO2015153761A3 (en) 2015-11-26
CA2944651A1 (en) 2015-10-08
EP3126375B1 (en) 2023-12-13
EP3126375A4 (en) 2018-01-24
US20170037084A1 (en) 2017-02-09

Similar Documents

Publication Publication Date Title
US10294273B2 (en) Macrocyclic peptidomimetics for alpha-helix mimicry
AU2024200512B2 (en) Stabilized peptide-mediated targeted protein degradation
JP6785932B2 (ja) 構築されたポリペプチド特異性のモジュレーション
JP6259861B2 (ja) ビス−スルフヒドリル大環状化系
US10300109B2 (en) Peptidomimetic macrocycles
DK2118123T3 (en) Stabilized p53 peptides and uses thereof
US10227380B2 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US20120178700A1 (en) Peptidomimetic macrocycles
JP2015509940A (ja) ペプチドミメティック大環状化合物
WO2010034029A1 (en) Peptidomimetic macrocycles
CA2995479A1 (en) Peptides binding to bfl-1
HK40126659A (zh) 稳定肽-介导的靶向蛋白降解
AU2016210709A1 (en) Stabilized p53 peptides and uses thereof
AU2017201310A1 (en) Bis-sulfhydryl macrocyclization systems
HK1137184B (en) Bis-sulfhydryl macrocyclization systems

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170426